ORLANDO - The investigational oral anticoagulant rivaroxaban was not inferior to a combination of the low-molecular-weight heparin enoxaparin and a vitamin K antagonist for reducing risk of recurrent deep venous thromboembolism for up to 1 year, reported investigators with the EINSTEIN Acute DVT study.In an open-label study, venous thromboembolism (VTE) or pulmonary embolism recurred in 2.1% of 1,731 patients randomized to rivaroxaban and in 3.0% of 1,718 patients randomized to enoxaparin...